US FDA approves AbbVie-Pfizer's treatment for intra-abdominal infections
AbbVie said that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections on Friday. AbbVie and co-developer Pfizer's drug, Emblaveo, is approved in combination with an antibiotic medication for patients 18 years and older with such infections.
AbbVie Gets FDA Approval of Intravenous Antibiotic Emblaveo
Emblaveo was jointly developed with Pfizer. AbbVie holds U.S. and Canada commercialization rights, with Pfizer responsible for commercialization in all other areas. Last April, the European Commission granted marketing authorization for treatment of adults with complicated intra-abdominal infections,
AbbVie says FDA approves Emblaveo in combination with metronidazole in adults
AbbVie (ABBV) announced that the U.S. Food and Drug Administration has approved EMBLAVEO, as the first and only fixed-dose, intravenous,
AbbVie gets FDA approval for antibiotic treatment Emblaveo (update)
AbbVie (NYSE:ABBV) said it has received FDA approval for the intravenous antibiotic treatment Emblaveo, which was co-developed with Pfizer (NYSE:PFE). The FDA approved Emblaveo, a combination of aztreonam and avibactam,
FDA approves novel antibiotic EMBLAVEO for cIAI
NORTH CHICAGO, Ill. - The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam) for the treatment of adults with complicated intra-abdominal infections (cIAI) with limited or no treatment options,
Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B
Shares of Intra-Cellular Therapies are surging 35% in premarket trading Monday after Johnson & Johnson said it will acquire the biopharmaceutical company for roughly $14.6 billion.
Johnson & Johnson Acquires Intra-Cellular in $14.6 Billion Deal
Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...
InvestmentNews8d
Advisors explain how to keep intra-family loans from fracturing relationships
Liebman added that structure is of critical importance when it comes to intra-family loans. At a minimum, the loan should be ...
Canaccord cuts Intra-Cellular stock rating, raises target to $132
Canaccord Genuity analysts downgraded Intra-Cellular Therapies (NASDAQ:ITCI) stock from Buy to Hold, adjusting the price target to $132 from the previous $119. The revision follows the recent ...
Yahoo Finance24d
Why Intra-Cellular (ITCI) Led the Monday Upsurge?
We recently published a list of 10 Firms Dominate Monday Upsurge. In this article, we are going to take a look at where Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) stands against other firms that ...
MedPage Today25d
Intra-Arterial Lytics After Successful Stroke Thrombectomy Did Not Improve Outcomes
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Two randomized trials found that intra-arterial urokinase and tenecteplase did not improve functional outcomes after ...